Vanina de Verneuil, Executive Vice President, General Counsel, and Corporate Secretary of Vir Biotechnology, Inc., filed a Form 4 on November 4, 2026, disclosing two sales of common stock totaling 3,750 shares on November 2 and November 3, 2026, under a Rule 10b5-1 trading plan.
Key Highlights
- First transaction: 1,343 shares of common stock were disposed of on November 2, 2026, at a price of $11.334 per share.
- Second transaction: 2,407 shares of common stock were disposed of on November 3, 2026, at a price of $11.1 per share.
- Post-transaction ownership: Following the reported transactions, de Verneuil directly held 110,193 shares of common stock.
- Tax withholding sale: The November 2 sale is described as "an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units" and "does not represent a discretionary trade by the Reporting Person," according to the filing.
- 10b5-1 plan: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
- ESPP shares included: The post-November 2 share count of 112,600 includes 961 shares acquired on May 29, 2026, pursuant to an employee stock purchase program, according to the filing.
De Verneuil's November 2026 Share Disposals at Vir Biotechnology
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Vanina de Verneuil, who serves as EVP, General Counsel, and Corporate Secretary at Vir Biotechnology, Inc. (NASDAQ:VIR), reported two separate disposals of common stock occurring on consecutive trading days. The filing was signed on November 4, 2026, by Lorin Wagner as Attorney-In-Fact.
The first disposal, on November 2, 2026, involved 1,343 shares sold at $11.334 each. The filing states this was "an automatic and mandatory sale" tied to the vesting of restricted stock units, intended to cover the company's tax withholding obligations, and carried out under a pre-established Rule 10b5-1 arrangement. Following that transaction, de Verneuil's directly held position stood at 112,600 shares, a figure the filing notes includes 961 shares acquired through an employee stock purchase program on May 29, 2026.
The second disposal, on November 3, 2026, involved 2,407 shares sold at $11.1 each, also conducted under a Rule 10b5-1 trading plan that the reporting person adopted on May 26, 2026. After this transaction, de Verneuil's directly held beneficial ownership totaled 110,193 shares. No derivative securities transactions were reported in connection with this filing.
What Was Disclosed
The filing disclosed two open-market sales of Vir Biotechnology common stock by EVP and General Counsel Vanina de Verneuil on November 2 and November 3, 2026, totaling 3,750 shares, executed under a pre-adopted Rule 10b5-1 plan, leaving her with 110,193 shares held directly.




Please wait processing your request...